Table 3.
Characteristics of cases diagnosed within 2 years from blood draw (N=93)
| Cancer type | ≤12 months N(%) |
13–24 months N(%) |
|---|---|---|
| Ovarian | 48 (71.6) | 23 (88.5) |
| Primary peritoneal | 10 (14.9) | 3 (11.5) |
| Fallopian tube | 9 (13.4) | 0 (0.0) |
| Histologic type | ||
| Serous cystadenocarcinoma | 40 (59.7) | 14 (53.8) |
| Mucinous cystadenocarcinoma | 1 (1.5) | 0 (0.0) |
| Endometrioid adenocarcinoma | 7 (10.4) | 5 (19.2) |
| Clear Cell Cystadenocarcinoma | 3 (4.5) | 1 (3.8) |
| Undifferentiated Carcinoma | 1 (1.5) | 0 (0.0) |
| Other | 2 (3.0) | 0 (0.0) |
| Adenocarcinoma, NOS/ Carcinoma, NOS | 11 (16.4) | 5 (19.2) |
| Malignant granulosa | 2 (3.0) | 1 (3.8) |
| Stage | ||
| Stage I/II | 17 (25.4) | 11 (42.3) |
| Stage III | 42 (62.7) | 9 (34.6) |
| Stage IV | 8 (11.9) | 5 (19.2) |
| Unknown | 0 (0.0) | 1 (3.8) |
| Grade | ||
| Well differentiated | 2 (3.0) | 3 (11.5) |
| Moderately differentiated | 13 (19.4) | 5 (19.2) |
| Poorly differentiated | 41 (61.2) | 14 (53.8) |
| Unknown | 11 (16.4) | 4 (15.4) |
| Mode of Detection | ||
| Screen Detected | 49 (73.1) | 1 (3.8) |
| CA125+; TVU− | 17 | 0 |
| CA125+; TVU+ | 15 | 0 |
| CA125+; TVU not done | 8 | 0 |
| CA125− TVU+ | 9 | 1 |
| Not Screen Detected | 18 (26.9) | 25 (96.2) |
| CA125−; TVU− | 9 | 16 |
| CA125−; TVU not done | 7 | 8 |
| ߓCA125 not done; TVU not done | 2 | 1 |
| Total | 67 | 26 |